Marco Cerrano
YOU?
Author Swipe
View article: Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351. Open
CPX-351, a novel liposomal formulation of cytarabine and daunorubicine, represents the standard of care in fit patients with myelodysplasia-related changes (AML-MRC) and therapy-related Acute Myeloid Leukemia (tAML). Considering its better…
View article: Real World Study on the Best <scp>CPX</scp> ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation
Real World Study on the Best <span>CPX</span> ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation Open
In the registration clinical trial 301 (NCT01696084), CPX‐351 has shown to be superior to conventional 3 + 7 in secondary AML (s‐AML). However, the optimal duration of treatment, the best timing for allogeneic stem cell transplantation (al…
View article: Mechanisms of Resistance to CAR T-Cells and How to Overcome Them
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them Open
In the last few decades, chimeric antigen receptor (CAR) T-cell therapy has led to a paradigm shift in the treatment of hematological malignancies, including various subtypes of B-cell non-Hodgkin’s lymphoma, B-cell acute lymphoblastic leu…
View article: Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm
Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm Open
Background/Objectives. Recent evidence underscores the prognostic and classificatory relevance of somatic mutations in myelodysplastic neoplasms (MDSs) and acute myeloid leukemia (AML). Methods. This prospective study assessed gene mutatio…
View article: Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group Open
View article: Real World Incidence and Etiology of Infectious Complications in Adults With Ph‐Negative Acute Lymphoblastic Leukemia Treated With the Pediatric‐Inspired GIMEMA LAL1913 Program. A Campus All Study
Real World Incidence and Etiology of Infectious Complications in Adults With Ph‐Negative Acute Lymphoblastic Leukemia Treated With the Pediatric‐Inspired GIMEMA LAL1913 Program. A Campus All Study Open
Infections often complicate pediatric‐inspired treatments for adult Philadelphia‐negative acute lymphoblastic leukemia (Ph‐ ALL). Literature data on these complications are difficult to interpret due to the heterogeneity of types of infect…
View article: Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study
Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study Open
Treatment‐free remission (TFR) in chronic myeloid leukemia (CML) can be considered for patients in sustained deep molecular response (DMR) who can discontinue tyrosine kinase inhibitors (TKIs) while maintaining responses. Studies suggest t…
View article: Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study Open
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the best consolidative treatment for high-risk acute lymphoblastic leukemia (ALL). The Campus ALL study group analyzed the clinical outcomes of patients treated in the real-l…
View article: SETD2 loss of function is a recurrent event in advanced‐phase chronic myeloid leukemia and contributes to genomic instability
SETD2 loss of function is a recurrent event in advanced‐phase chronic myeloid leukemia and contributes to genomic instability Open
The SETD2 tumour suppressor encodes a histone methyltransferase that specifically trimethylates histone H3 on lysine 36 (H3K36me3), a key histone mark implicated in the maintenance of genomic integrity among other functions. We found that …
View article: Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML
Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML Open
The standard induction treatment for acute myeloid leukemia (AML) has limited efficacy for patients with non–low-risk AML. We conducted a multicenter study phase 1b/2, Gruppo Italiano Malattie EMatologiche dell'Adulto AML1718, to investiga…
View article: Breast Isolated FLT3 Positive AML Relapse Treated with Gilteritinib in Monotherapy: Long- Term Follow-Up and Review of the Literature
Breast Isolated FLT3 Positive AML Relapse Treated with Gilteritinib in Monotherapy: Long- Term Follow-Up and Review of the Literature Open
Extramedullary relapse of acute myeloid leukemia (AML) is a relatively common occurrence, with the FMS-like tyrosine kinase 3 (FLT3) mutation being a significant risk factor. While gilteritinib is approved for treating relapsed/refractory …
View article: Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia: Results of a Single-Center Study
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia: Results of a Single-Center Study Open
Background: Despite the adoption of pediatric-like chemotherapy protocols, the introduction of new immunotherapies and a better understanding of the oncogenic landscape, the outcome for adult patients with acute lymphoblastic leukemia (ALL…
View article: Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents Open
We evaluated response to VEN/HMA in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease (EMD). Median age was 65 (range, 19-81) years. Patients had a median of two EMD sites (range, 1-5) and 35 (76%) patie…
View article: Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry Open
View article: Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study Open
The introduction of pediatric-inspired regimens in adult Philadelphia-negative acute lymphoblastic leukemia (Ph-ALL) has significantly improved patients’ prognosis. Within the Campus ALL network we analyzed the outcome of adult Ph-ALL pati…
View article: Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study Open
Lenalidomide (LEN) can induce red blood cell-transfusion independence (RBC-TI) in 60-70% of del(5q) myelodysplastic neoplasm (MDS) patients. Current recommendation is to continue LEN in responding patients until failure or progression, wit…
View article: Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic syndrome: a HARMONY Alliance study
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic syndrome: a HARMONY Alliance study Open
Lenalidomide (LEN) can induce RBC transfusion independence (RBC-TI) in 60–70% of del(5q) myelodysplastic syndrome (MDS) patients. Current recommendation is to continue LEN in responding patients until failure or progression, with likelihoo…
View article: Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission
Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission Open
View article: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry Open
View article: Maintain Efficacy and Spare Toxicity: Traditional and New Radiation-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation
Maintain Efficacy and Spare Toxicity: Traditional and New Radiation-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation Open
Novelty in total body irradiation (TBI) as part of pre-transplant conditioning regimens lacked until recently, despite the developments in the field of allogeneic stem cell transplants. Long-term toxicities have been one of the major conce…
View article: Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia
Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia Open
Blinatumomab, a CD3/CD19 bispecific antibody categorized under BiTEs (bispecific T-cell engagers), has recently gained approval as a standard of care in B-cell acute lymphoblastic leukemia (B-ALL) [1,2].Despite its efficacy, the emergence …
View article: Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions
Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions Open
In the last decade, anti-CD19 CAR-T cell therapy has led to a treatment paradigm shift for B-cell non-Hodgkin lymphomas, first with the approval for relapsed/refractory (R/R) large B-cell lymphomas and subsequently for R/R mantle cell and …
View article: Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease Open
We evaluated 58 patients with relapsed or refractory (r/r) acute B-lymphoblastic leukemia (B-ALL; median age, 42.5 years; range, 16-69 years), treated with inotuzumab ozogamicin (INO) between 2016-2022 and who received an allogeneic hemato…
View article: Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol
Multicenter Campus ALL Study on Infectious Complications in Ph- Acute Lymphoblastic Leukemia Patients Treated in the Real Life with the Gimema LAL1913 Protocol Open
Background The Italian national program of pediatric-inspired chemotherapy GIMEMA LAL1913 trial for adult Ph- acute lymphoblastic leukemia (Ph- ALL) has reported favorable results particularly in the younger subgroup of patients (pts) aged…
View article: Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study
Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study Open
Background: CPX-351, has been approved for the treatment of patients diagnosed with Acute Myeloid Leukemia (AML) arising from a previous myelodysplastic syndrome (s-AML) or secondary to chemotherapy (t-AML) as per former WHO 2016 classific…
View article: Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study Open
Background: Blinatumomab (Blina) and inotuzumab ozogamicin (InO) has improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). However, little is known about the outcome after recurrence and re-treatment with immuno…
View article: Characteristics and outcomes of patients with acute myeloid leukemia admitted to intensive care unit with acute respiratory failure: a post-hoc analysis of a prospective multicenter study
Characteristics and outcomes of patients with acute myeloid leukemia admitted to intensive care unit with acute respiratory failure: a post-hoc analysis of a prospective multicenter study Open
Background Acute respiratory failure (ARF) is the leading cause of intensive care unit (ICU) admission in patients with Acute Myeloid Leukemia (AML) and data on prognostic factors affecting short-term outcome are needed. Methods This is a …
View article: Risk of progression in chronic <scp>phase‐chronic</scp> myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the <scp>TFR‐PRO</scp> study
Risk of progression in chronic <span>phase‐chronic</span> myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the <span>TFR‐PRO</span> study Open
Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP‐CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. However, recent reports…
View article: S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY Open
Background: Lenalidomide can lead to red blood cell-transfusion independence (RBC-TI) in 60-70% of del(5q) transfusion dependent MDS patients, and to complete cytogenetic response (CCyR) in 30-40% of them. Currently, patients achieving RBC…
View article: PB1811: REAL LIFE APPLICATION OF NEXT GENERATION SEQUENCING IN ACUTE MYELOID LEUKEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS: A SINGLE CENTER EXPERIENCE
PB1811: REAL LIFE APPLICATION OF NEXT GENERATION SEQUENCING IN ACUTE MYELOID LEUKEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS: A SINGLE CENTER EXPERIENCE Open
Topic: 3. Acute myeloid leukemia - Biology & Translational Research Background: Advances in molecular biology have improved understanding and prognostic classification of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as…